Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2024-01-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物第二届监事会2024年第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the Supervisory Board (监事会) of 益方生物科技（上海）股份有限公司 regarding resolutions passed at their 2024 second meeting. It details the meeting attendance, compliance with company law, and approval of specific agenda items related to the company's restricted stock incentive plan, including the vesting of shares and cancellation of unvested shares. The document does not contain financial statements or detailed financial analysis but is a formal disclosure of board resolutions. It references other announcements for detailed information. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short and focused on board resolutions, not a full report or financial release.
2024-01-19 Chinese
君合律师事务所上海分所关于益方生物科技（上海）股份有限公司2022年限制性股票激励计划首次授予部分第一个归属期归属条件成就及部分限制性股票作废事项的法律意见书
Remuneration Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan of a company, specifically about the first vesting period's achievement of conditions and partial cancellation of restricted stocks. It discusses legal compliance, approvals, authorizations, and disclosures related to the stock incentive plan. The document is not a financial report, earnings release, or management discussion, but a legal opinion on a corporate governance and compensation matter related to stock incentives. This fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation plans and related legal opinions for executives and employees. The document is detailed and substantive, not a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the classification is DEF 14A with high confidence.
2024-01-19 Chinese
益方生物监事会关于2022年限制性股票激励计划首次授予部分第一个归属期归属名单的核查意见
Remuneration Information Classification · 95% confidence The document is a supervisory board opinion on the verification of the first vesting period list of a 2022 restricted stock incentive plan. It references compliance with company law, securities law, and stock incentive management regulations. The content focuses on the verification and approval of the vesting list for the stock incentive plan, which relates to remuneration and compensation matters for executives or employees. The document is short (786 characters) and is not a full report but a formal opinion or statement regarding the stock incentive plan. This fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors, including stock incentive plans.
2024-01-19 Chinese
益方生物独立董事关于公司第二届董事会2024年第二次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on proposals from the company's second board meeting in 2024. It discusses approval of stock incentive plans and related corporate governance matters. There is no financial data, earnings information, or regulatory filings referenced. The document is a formal opinion related to board meeting agenda items, specifically about stock incentive plans and their compliance with laws and company rules. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management decisions and opinions. The document length is short and focused on governance and board meeting matters, not a full report or announcement of a report publication.
2024-01-19 Chinese
益方生物关于2022年限制性股票激励计划首次授予部分第一个归属期符合归属条件的公告
Director's Dealing Classification · 95% confidence The document is a detailed announcement regarding the 2022 restricted stock incentive plan of the company, specifically about the first vesting period of the initial grant of restricted shares that meet the vesting conditions. It includes information about the stock incentive plan, the number of shares vested, the conditions for vesting, the approval and decision-making process by the board and supervisory committee, legal opinions, and detailed tables of vesting schedules and performance targets. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not a call transcript, earnings release, or capital update. It is a regulatory announcement about the vesting of restricted stock under an equity incentive plan, which is a form of director/executive share dealing or insider share transactions. Therefore, the most appropriate classification is Director's Dealing (DIRS). The document length and detail support a high confidence in this classification.
2024-01-19 Chinese
益方生物关于向2022年限制性股票激励计划激励对象授予预留部分限制性股票（第二批）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the granting of reserved restricted shares under a 2022 restricted stock incentive plan. It details the number of shares granted, the grant date, the price, the recipients, the approval process by the board and supervisory committee, legal and financial advisor opinions, and accounting treatment of the stock-based compensation. The document is a formal announcement of a share-based incentive plan grant, which is a capital/financing activity related to equity issuance to employees or management. It is not a full financial report, audit report, or management discussion, nor is it a voting result or a regulatory filing of a different nature. The document is about the issuance of shares under an incentive plan, which fits best under Capital/Financing Update (CAP). The document length is 8808 characters, which is substantive and contains detailed information about the share grant, not just a brief notice or a report publication announcement. Therefore, the classification is CAP with high confidence.
2024-01-05 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.